VFA
ALDR

Virtus Fund Advisers’s Alder Biopharmaceuticals ALDR Stock Holding History

Virtus Fund Advisers’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$368K Buy
+32,153
New +$359K ﹤0.01% 381
2014
Q3 		– Sell
-682
Closed -$14K – 2268
2014
Q2 		$14K Buy
+682
New +$9.6K ﹤0.01% 2650

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Virtus Fund Advisers's ALDR Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Alder Biopharmaceuticals (ALDR) in Q4 2017: 32,153 shares worth $368K. The stake represents ﹤0.01% of the portfolio and ranks #381 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in ALDR as recently as Q2 2014.

Virtus Fund Advisers first reported a position in ALDR in Q2 2014 and has held it in 2 quarters since. 140 funds tracked by Wall St. Rank hold ALDR as of Q4 2017.

  • Virtus Fund Advisers held 32,153 shares of Alder Biopharmaceuticals worth $368K as of Q4 2017.
  • Alder Biopharmaceuticals was a new Virtus Fund Advisers position in Q4 2017.
  • Alder Biopharmaceuticals made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #381 holding.
  • Virtus Fund Advisers first reported a position in Alder Biopharmaceuticals in Q2 2014 and has held it in 2 quarters since.
  • 140 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.